Related Experiment Video
Updated: Oct 18, 2025
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Clinical biomarkers in soft tissue sarcoma A comprehensive review of current soft tissue sarcoma biomarkers
Soumya R Sharma1, Nadia E Paonessa1, Lucia Casadei1
1James Cancer Hospital Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
Abstract:
Soft tissue sarcomas (STS) are a heterogeneous group of tumors that arise from mesenchymal tissue. Investigation at the molecular level has been challenging due to the rarity of STS and the number of histologic subtypes. However, recent research has provided new insight into potential genomic, proteomic, and immunological biomarkers of STS. The identification of biomarkers can improve diagnosis, prognosis, and prediction of recurrence and treatment response. This review provides an understanding of biomarkers, discussing the current status of biomarker research in STS.
Insights
This review discusses biomarkers for soft tissue sarcomas (STS), which are rare tumors. Identifying these molecular markers can improve STS diagnosis, prognosis, and treatment selection.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Soft tissue sarcomas (STS) represent a diverse class of tumors originating from mesenchymal tissues.
- Investigating STS at the molecular level is complicated by their rarity and numerous histologic subtypes.
- Recent advancements offer new insights into potential genomic, proteomic, and immunological biomarkers for STS.
Purpose of the Study:
- To review the current landscape of biomarker research in soft tissue sarcomas.
- To elucidate the role of biomarkers in improving the diagnosis and prognosis of STS.
- To explore how biomarkers can predict recurrence and guide treatment strategies for STS.
Main Methods:
- Literature review of recent research on STS biomarkers.
- Analysis of genomic, proteomic, and immunological marker studies.
- Synthesis of current understanding of biomarker applications in STS.
Main Results:
- Biomarker identification is crucial for advancing STS understanding.
- Genomic, proteomic, and immunological markers show promise for STS.
- Biomarkers can enhance diagnostic accuracy and prognostic prediction in STS.
Conclusions:
- Biomarkers are essential for personalized medicine approaches in STS.
- Continued research into STS biomarkers will refine clinical management.
- Understanding biomarkers is key to improving outcomes for patients with soft tissue sarcomas.
